肥胖对棘白菌素治疗念珠菌感染疗效的影响:一项回顾性观察队列研究

IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES Infection and Drug Resistance Pub Date : 2024-07-09 DOI:10.2147/idr.s462301
Ahmad Aljohani, Saeed Alqahtani
{"title":"肥胖对棘白菌素治疗念珠菌感染疗效的影响:一项回顾性观察队列研究","authors":"Ahmad Aljohani, Saeed Alqahtani","doi":"10.2147/idr.s462301","DOIUrl":null,"url":null,"abstract":"<strong>Introduction:</strong> Echinocandins are used to treat invasive candidiasis (IC), with FDA-approved doses indicated for both obese and non-obese patients. Pharmacokinetic (PK) studies have identified subtherapeutic exposure in obese patients receiving standard doses (SDs) of echinocandins. However, research on clinical outcome differences of echinocandins’ SDs between obese and non-obese patients is lacking. Therefore, this study aimed to evaluate the effectiveness of echinocandins’ SDs in obese compared to normal-weight patients with IC.<br/><strong>Patients and Methods:</strong> This retrospective cohort study was conducted at King Saud University Medical City (KSUMC) from Jan 2017 to Feb 2023. The study included adult patients diagnosed with <em>Candida</em> infections who received ≥ 4 doses of echinocandins. Patients with body mass index (BMI) less than 18 kg/m<sup>2</sup> were excluded from the study. The primary and secondary outcomes included the total length of stay (LOS), IC duration, frequency of clinical resolution and all-cause mortality.<br/><strong>Results:</strong> This study included 132 patients (47 obese; 85 non-obese) with a median age of 61 years. The median BMI and weight were different between the obese (34.5 kg/m<sup>2</sup>, 88 kg) and non-obese (24 kg/m<sup>2</sup>, 65 kg) groups (P= 0.01). Micafungin and caspofungin were used in 63.6% and 36.4% of patients, respectively. The total LOS and length of IC infections were similar between both groups, with median values of 29.5 days (P= 0.896) and 18 days (P = 0.160), respectively. The clinical improvement percentages were 68.1% for obese and 65.9% for non-obese patients (P= 0.797), with all-cause mortality rates at 44.7% and 42.4%, respectively (P= 0.796).<br/><strong>Conclusion:</strong> The study found no clinical outcome differences between obese and non-obese patients, with Similar effectiveness of the echinocandins’ SDs in both groups. Further research in multi-centre settings is recommended to detect any potential differences between the two groups.<br/><br/><strong>Keywords:</strong> echinocandins, <em>candida</em>, obesity, effectiveness<br/>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Obesity on Echinocandin Effectiveness in Treating Candida Infections: A Retrospective Observational Cohort Study\",\"authors\":\"Ahmad Aljohani, Saeed Alqahtani\",\"doi\":\"10.2147/idr.s462301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Introduction:</strong> Echinocandins are used to treat invasive candidiasis (IC), with FDA-approved doses indicated for both obese and non-obese patients. Pharmacokinetic (PK) studies have identified subtherapeutic exposure in obese patients receiving standard doses (SDs) of echinocandins. However, research on clinical outcome differences of echinocandins’ SDs between obese and non-obese patients is lacking. Therefore, this study aimed to evaluate the effectiveness of echinocandins’ SDs in obese compared to normal-weight patients with IC.<br/><strong>Patients and Methods:</strong> This retrospective cohort study was conducted at King Saud University Medical City (KSUMC) from Jan 2017 to Feb 2023. The study included adult patients diagnosed with <em>Candida</em> infections who received ≥ 4 doses of echinocandins. Patients with body mass index (BMI) less than 18 kg/m<sup>2</sup> were excluded from the study. The primary and secondary outcomes included the total length of stay (LOS), IC duration, frequency of clinical resolution and all-cause mortality.<br/><strong>Results:</strong> This study included 132 patients (47 obese; 85 non-obese) with a median age of 61 years. The median BMI and weight were different between the obese (34.5 kg/m<sup>2</sup>, 88 kg) and non-obese (24 kg/m<sup>2</sup>, 65 kg) groups (P= 0.01). Micafungin and caspofungin were used in 63.6% and 36.4% of patients, respectively. The total LOS and length of IC infections were similar between both groups, with median values of 29.5 days (P= 0.896) and 18 days (P = 0.160), respectively. The clinical improvement percentages were 68.1% for obese and 65.9% for non-obese patients (P= 0.797), with all-cause mortality rates at 44.7% and 42.4%, respectively (P= 0.796).<br/><strong>Conclusion:</strong> The study found no clinical outcome differences between obese and non-obese patients, with Similar effectiveness of the echinocandins’ SDs in both groups. Further research in multi-centre settings is recommended to detect any potential differences between the two groups.<br/><br/><strong>Keywords:</strong> echinocandins, <em>candida</em>, obesity, effectiveness<br/>\",\"PeriodicalId\":13577,\"journal\":{\"name\":\"Infection and Drug Resistance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-07-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Drug Resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/idr.s462301\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/idr.s462301","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

简介:棘白菌素类药物用于治疗侵袭性念珠菌病(IC),美国食品及药物管理局批准的剂量适用于肥胖和非肥胖患者。药代动力学(PK)研究发现,接受标准剂量(SD)棘白菌素治疗的肥胖患者的暴露量低于治疗量。然而,有关肥胖和非肥胖患者服用棘白菌素标准剂量后临床疗效差异的研究还很缺乏。因此,本研究旨在评估棘白菌素标准剂量在肥胖与正常体重的集成电路患者中的疗效:这项回顾性队列研究于 2017 年 1 月至 2023 年 2 月在沙特国王大学医学城(KSUMC)进行。研究对象包括确诊为念珠菌感染并接受过≥4次棘白菌素治疗的成年患者。体重指数(BMI)低于18 kg/m2的患者不在研究范围内。主要和次要结果包括总住院时间(LOS)、IC持续时间、临床缓解频率和全因死亡率:本研究共纳入 132 名患者(47 名肥胖;85 名非肥胖),中位年龄为 61 岁。肥胖组(34.5 千克/平方米,88 千克)和非肥胖组(24 千克/平方米,65 千克)的中位体重指数和体重不同(P= 0.01)。分别有 63.6% 和 36.4% 的患者使用米卡芬净和卡泊芬净。两组患者的总住院日和IC感染时间相似,中位值分别为29.5天(P= 0.896)和18天(P= 0.160)。肥胖患者和非肥胖患者的临床改善率分别为68.1%和65.9%(P= 0.797),全因死亡率分别为44.7%和42.4%(P= 0.796):研究发现,肥胖和非肥胖患者的临床结果没有差异,两组患者服用棘白菌素类 SDs 的疗效相似。建议在多中心环境中开展进一步研究,以发现两组患者之间的任何潜在差异。 关键词:棘白菌素、念珠菌、肥胖、有效性
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Impact of Obesity on Echinocandin Effectiveness in Treating Candida Infections: A Retrospective Observational Cohort Study
Introduction: Echinocandins are used to treat invasive candidiasis (IC), with FDA-approved doses indicated for both obese and non-obese patients. Pharmacokinetic (PK) studies have identified subtherapeutic exposure in obese patients receiving standard doses (SDs) of echinocandins. However, research on clinical outcome differences of echinocandins’ SDs between obese and non-obese patients is lacking. Therefore, this study aimed to evaluate the effectiveness of echinocandins’ SDs in obese compared to normal-weight patients with IC.
Patients and Methods: This retrospective cohort study was conducted at King Saud University Medical City (KSUMC) from Jan 2017 to Feb 2023. The study included adult patients diagnosed with Candida infections who received ≥ 4 doses of echinocandins. Patients with body mass index (BMI) less than 18 kg/m2 were excluded from the study. The primary and secondary outcomes included the total length of stay (LOS), IC duration, frequency of clinical resolution and all-cause mortality.
Results: This study included 132 patients (47 obese; 85 non-obese) with a median age of 61 years. The median BMI and weight were different between the obese (34.5 kg/m2, 88 kg) and non-obese (24 kg/m2, 65 kg) groups (P= 0.01). Micafungin and caspofungin were used in 63.6% and 36.4% of patients, respectively. The total LOS and length of IC infections were similar between both groups, with median values of 29.5 days (P= 0.896) and 18 days (P = 0.160), respectively. The clinical improvement percentages were 68.1% for obese and 65.9% for non-obese patients (P= 0.797), with all-cause mortality rates at 44.7% and 42.4%, respectively (P= 0.796).
Conclusion: The study found no clinical outcome differences between obese and non-obese patients, with Similar effectiveness of the echinocandins’ SDs in both groups. Further research in multi-centre settings is recommended to detect any potential differences between the two groups.

Keywords: echinocandins, candida, obesity, effectiveness
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infection and Drug Resistance
Infection and Drug Resistance Medicine-Pharmacology (medical)
CiteScore
5.60
自引率
7.70%
发文量
826
审稿时长
16 weeks
期刊介绍: About Journal Editors Peer Reviewers Articles Article Publishing Charges Aims and Scope Call For Papers ISSN: 1178-6973 Editor-in-Chief: Professor Suresh Antony An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.
期刊最新文献
Risk Factors for Multidrug Resistance in Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Nomogram. Microbiological Characteristics, Risk Factors, and Short-Term Mortality of Carbapenem-Resistant Enterobacteriaceae Bloodstream Infections in Pediatric Patients in China: A 10-Year Longitudinal Study. Clinical Characteristics, Species Distribution, and Drug Resistance of Non-Tuberculous Mycobacteria Lung Disease in Qingdao, China. A Regional-Scale Assessment-Based SARS-CoV-2 Variants Control Modeling with Implications for Infection Risk Characterization. Disseminated Combined Talaromyces marneffei and Enterococcus faecium Bloodstream Infection Presenting as Gastrointestinal Perforation in a Patient with CARD9 Gene Mutation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1